Attention javascript est désactivé sur votre poste.
Ce site nécessite l'activation de javascript pour fonctionner correctement.
Follow our news on LinkedIn
Learn more
Follow our news on LinkedIn
Learn more
Our pipeline
OPM 101
OPM 102
OPM 201
COMETE
Partnering
Scientific news
Our innovation technologies
OncoSNIPER
Nanocyclix®
PROMETHE®
Investors
Message from the President
Investor Day 2023
Regulated informations [FR]
Press Releases
General Meetings [FR]
About us
Latest news
Our history
Management
Our HR policy
FederAidd
PROMETHE sector
CSR
Our approach
Our code of ethics and business conduct
Our carbon footprint
Contact us
Press Release
News
Press Release
Mon. 24 March 2025
OPM announces Protocol Submission for its Phase 1b/2a Study
Read more
News
Press Release
Tue. 4 March 2025
Nomination of Christophe Thurieau as an independent member of OPM Board of Directors
Read more
News
Press Release
Mon. 6 January 2025
4th Letter to Shareholders
Read more
News
Press Release
Fri. 20 December 2024
OPM reacquires rights to its OPM-201 program from Servier after a positive Phase I trial in healthy volunteers
Read more
News
Press Release
Tue. 22 October 2024
OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101
Read more
News
Press Release
Tue. 15 October 2024
OPM announces poster presentation on OPM-101
Read more
Financial
News
Press Release
Wed. 25 September 2024
OPM announces its first-half 2024 results and provides an update on its clinical developments, and its financial situation
Read more
News
Press Release
Tue. 16 July 2024
OPM announces positive results of phase 1 healthy volunteers of OPM-101
Read more
Financial
News
Press Release
Mon. 24 June 2024
Letter to the shareholders n°3
Read more
1
2
3
4